Vaginal DHEA for Women After Breast Cancer

Hadassah Medical Organization

Overview

There does not appear to be a consensus regarding the treatment of vaginal dryness in women who have a contraindication to the use of estrogen products. DHEA, when used locally, may improve the symptoms of vaginal dryness due to its chemical properties.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Conditions

Vaginal Dryness Breast Cancer Urinary Incontinence Quality of Life Sexual Satisfaction

Interventions

Vaginal DHEADRUG

PlaceboDRUG

Eligibility

Sex: FEMALEMin age: 35 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * women post menopausal aged 35-55, suffering from vaginal dryness, secondary to chemotherapy for breast cancer, within 5 years of diagnosis. Follicle Stimulating Hormone and Estradiol levels in the post menopausal range are needed. Exclusion Criteria: * women using products to alleviate vaginal dryness. * women taking medication for urinary incontinence * women not sexually active, for other reasons.

Locations (1)

Hadassah Medical Organization

Jerusalem, Israel

Outcomes

Primary Outcomes

improvement in vaginal dryness

Time frame: 12 weeks

Secondary Outcomes

improvement in urinary incontinence

Time frame: 12 weeks

improvement in sexual satisfaction

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.